GSK3B and esophageal squamous cell carcinoma: Activating mutations or abnormalities in the PI3K-AKT pathway in ESCC are particularly intriguing, as these contribute to the inactivation of the downstream GSK3β, and GSK3β is known to induce NRF2 activation [5].